Perth, July 21, 2016 - (ABN Newswire) - MMJ PhytoTech Ltd (ASX:MMJ) are pleased to provide the Company’s latest Investor Presentation for July 2016, ‘From Farm to Pharma’.
MMJ PhytoTech at a Glance
- MMJ PhytoTech(‘MMJ’) is a vertically-integrated biopharmaceutical company focused on developing and commercializing Medical Cannabis (‘MC’) based therapeutics
- The Company was formed from the July 2015 merger of MMJ Bioscience (Can PrivCo) and PhytoTech Medical (Aust. PubCo) and is traded on the ASX under the symbol ‘MMJ’
- MMJ’s unique “Farm to Pharma” strategic platform integrates the entire MC pharmaceutical supply chain combining MC cultivation with pharmaceutical processing / advanced delivery technologies and R&D / clinical development -unlocking the full value of the Company’s MMPR assets
- The “Farm to Pharma” integration is essential for the development and supply of MC-based pharmaceuticals but also provides the company with several near-and mid-term pre-pharma revenue sources
- Currently, MMJ is ramping up production at its MMPR facility in Canada, growing revenues from sales of its exclusive Gelpell(R) CBD Capsules in the EU and preparing for the Q4 2016/Q1 2017 commencement of two Phase 2 Clinical trials using Gelpell(R) THC/CBD and Gelpell(R) CBD capsule for MS and Epilepsy indications respectively
To view the presentation, please visit: http://abnnewswire.net/lnk/X40506B6
WEB: Investor Presentation
About: MMJ PhytoTech Ltd
MMJ PhytoTech Limited (ASX:MMJ) is a Medical Cannabis company, which aims to commercialise Medical Grade Cannabis (MGC) and high potential cannabis based therapeutics products to the rapidly growing international market with regulated medical cannabis laws. The Company operates three subsidiaries with operations across the entire Medical Cannabis value chain, encompassing the Company’s “Farm to Pharma” strategy.
It’s United Greeneries subsidiary has growing facilities in Canada and is fully integrated with Agrichem Analytical, its quality control and testing laboratory. Satipharm has a number of key international distribution partnerships for the distribution of cannabinoid-based pharmaceutical, nutraceutical and wellness products.
Through its PhytoTech Therapeutics subsidiary in Israel the Company has an exclusive research and licensing agreement with Yissum, the prestigious Research Development and technology transfer Company of Hebrew University in Jerusalem, Israel, a global leader in medical cannabis research.
